

Pioneering Access for Patients: The Sandoz company presentation



Our Purpose

Pioneering Access for Patients





An overview of who we are



A Novartis Division

We are uniquely positioned as an industry-leading division of Novartis (USD 52 bn 2018 sales)



A Global Leader

We have leading positions in biosimilars, antibiotics and generic oncology



A Broad Portfolio

We cover all major therapeutic areas and geographic regions with our broad portfolio of off-patent medicines



A True Partner

We work closely with commercial and scientific partners to maximize our collective contribution to society.



¹ IQVIA through December 2018, #1 in antibiotics (by volume), generic oncology (by sales); #2 in biosimilars (by sales); first FDA-cleared PDT (reSET)

We are the global generic leader in antibiotic medicines¹



 Antibiotics are the cornerstone of global healthcare – generics represent the majority of the global market²



 As the global leader in generic antibiotics, we play a key role in keeping healthcare sustainable



 Antimicrobial resistance (AMR) could lead to an estimated 10m more deaths annually by 2050, unless society acts now³





^{1.} IQVIA through 2019

^{2. 76%} by volume, 62% by value (IMS through 2016)

^{43.} Review on Antimicrobial Resistance, 2016

We are also the global leader in generic oncology medicines



 Leading global generic oncology portfolio of >50 products, from chemotherapy, via hormones and supportive care, to biologics¹



 Our oncology medicines reach patients in nearly 100 countries



 Sandoz Oncology offering is strongly complementary to leading innovative presence of Novartis Oncology





We are a leader in biosimilars, with eight marketed products





















THANK YOU

